Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
-2.22%
$46.35
0% positive prob.
5-Day Prediction
-6.36%
$44.39
0% positive prob.
20-Day Prediction
-8.40%
$43.42
0% positive prob.
| Quarter | Signal | 1D Return | 5D Return | 20D Return | Confidence | Actual 5D |
|---|---|---|---|---|---|---|
| Q1 2026 | SELL | -2.22% | -6.36% | -8.40% | 99.9% | Pending |
| Q4 2025 | SELL | -1.85% | -6.11% | -6.36% | 100.0% | -7.60% |
SEC 8-K filings with transcript text
May 6, 2026 · 100% conf.
1D
-2.22%
$46.35
5D
-6.36%
$44.39
20D
-8.40%
$43.42
2 tech-20260506xex99d1.htm
Exhibit 99.1
Bio-Techne Releases Third Quarter Fiscal 2026 Results
Minneapolis/May 6, 2026/ Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the third quarter ending March 31, 2026.
Third Quarter FY2026 Highlights
●Reported and organic revenue declined 2% to $311.4M, negatively impacted by prior-year GMP fast-track orders and timing of large Commercial Supply shipments
●GAAP EPS increased to $0.32 from $0.14; adjusted EPS was $0.53, down from $0.56
●Large pharma delivered the sixth consecutive quarter of double-digit growth, offset by a continued lag in spending by emerging biotech; U.S. academic markets stabilized with low-single-digit growth
●Growth vectors performed well, with mid-single-digit growth in Proteomic Analysis instruments, mid-teens growth in Spatial Biology, and nearly 50% growth in GMP proteins excluding fast-track customers
“The Bio-Techne team delivered solid execution amid a mixed end-market environment,” said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. “Large pharma again led results with the sixth consecutive quarter of double-digit growth, supported by momentum in Asia and stabilizing U.S. academic demand. While biotech funding remains healthy, it has not yet translated into broad-based demand across our portfolio.”
Kelderman continued, “We are encouraged by early indicators pointing to a more constructive outlook as funding activity and customer purchasing begin to realign. Our portfolio is organized to support durable, high-value applications across the scientific journey, from biological discovery and translational insight to therapeutic development, manufacturing, and precision diagnostics. Together with our strong operating discipline and financial flexibility, Bio-Techne remains well positioned to deliver attractive long-term value for our stakeholders.”
Conference Call
Bio-Techne will host an earnings conference call today, May 6, 2026, at 8:00 a.m. CDT. To listen, please dial 1-800-343-4136 or 1-203-518-9843 (for international callers), and reference conference ID TECHQ3. The earnings call can also be accessed via webcast through the following link https://investors.bio-techne.com/ir-calendar.
A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512- 2921 or 1-412-317-6671 (for international callers) and referencing Conference ID 11161556. The replay will be available from 11:00 a.m. CDT on Wednesday, May 6, 2026, until 11:00 p.m. CDT on Saturday, June 6, 2026.
Third Quarter Fiscal 2026
Revenue
Net sales for the third quarter decreased 2% to $311.4 million. Organic revenue decreased 2% compared to the prior year, with foreign currency exchange having a favorable impact of 2%, and non-recurring prior year revenue from a business held-for-sale having an unfavorable impact of 2%.
GAAP Earnings Results
GAAP EPS was $0.32 per diluted share versus $0.14 in the same quarter last year. GAAP operating income for the third quarter of fiscal 2026 increased 95% to $75.5 million compared to $38.7 million in the third quarter of fiscal 2025. GAAP operating margin was 24.2% compared to 12.2% in the third quarter of fiscal 2025. Current quarter GAAP operating margin was favorably impacted by ongoing profitability initiatives, the Exosome Diagnostics divestiture, and a non-recurring arbitration payment in the prior year, partially offset by unfavorable product mix.
Non-GAAP Earnings Results
Adjusted EPS decreased to $0.53 per diluted share compared to $0.56 in the same quarter last year. Adjusted operating income decreased to $106.5 million in the third quarter of fiscal 2026 compared to $110.3 million in the third quarter of fiscal 2025. Adjusted operating margin was 34.2% for the third quarter of fiscal 2026 compared to 34.9% in the third quarter of fiscal 2025. Adjusted operating margin was unfavorably impacted by volume and product mix, partially offset by ongoing profitability initiatives and the Exosome Diagnostics divestiture.
Segment Results
Management uses adjusted operating results to monitor and evaluate performance of the Company’s business segments, as highlighted below.
Protein Sciences Segment
The Company’s Protein Sciences segment is one of the world’s leading suppliers of specialized proteins such as cytokines and growth factors, immunoassays, antibodies and reagents, to the biopharma and academic research communities. Additionally, the segment provides an array of platforms essential in various areas of protein analysis. The Protein Sciences segment’s third quarter fiscal 2026 net sales were $226.2 million, a decrease of 1% from $227.7 million in the third quarter of fiscal 2025. As of December 31, 2023, a business within the Protein Sciences segment met the criteria as held-for-sale; this held-for-sale busine
Feb 4, 2026 · 100% conf.
1D
-1.85%
$67.40
Act: -4.09%
5D
-6.11%
$64.47
Act: -7.60%
20D
-6.36%
$64.30
Act: -18.61%
BIO-TECHNE CORPORATION_February 4, 2026
0000842023false00008420232026-02-042026-02-04
Washington, DC 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2026
(Exact Name of Registrant as Specified in its Charter)
Minnesota 0-17272 41-1427402
(State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification Number)
55413
614 McKinley Place NE Minneapolis, Minnesota 55413
(Address of Principal Executive Offices) (Zip Code)
(612) 379-8854
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
☐ Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition A copy of the press release issued by Bio-Techne Corporation on February 4, 2026, describing the results of operations for the quarter and six months ended December 31, 2025, and its financial condition as of December 31, 2025 is attached hereto as Exhibit 99.1. The information in this Form 8-K and the Exhibits attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 8.01 Other Events A copy of the press release issued by Bio-Techne Corporation on February 4, 2026 announcing a cash dividend is attached hereto as Exhibit 99.2. Item 9.01 Financial Statements and Exhibits (d) Exhibits
99.1 Press Release, dated February 4, 2026, announcing results of operations
99.2 Press Release, dated February 4, 2026, announcing cash dividend
104 - Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 4, 2026 By: /s/ Shane V. Bohnen
Shane V. Bohnen
Senior Vice President, General Counsel and Secretary
Nov 5, 2025
BIO-TECHNE CORPORATION_October 30, 2025
0000842023false00008420232025-10-302025-10-30
Washington, DC 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2025
(Exact Name of Registrant as Specified in its Charter)
Minnesota 0-17272 41-1427402
(State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification Number)
55413
614 McKinley Place NE Minneapolis, Minnesota 55413
(Address of Principal Executive Offices) (Zip Code)
(612) 379-8854
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
☐ Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition A copy of the press release issued by Bio-Techne Corporation (the “Company”) on November 5, 2025, describing the results of operations for the quarter ended September 30, 2025 and its financial condition as of September 30, 2025 is attached hereto as Exhibit 99.1. The information in this Form 8-K and the Exhibits attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 5.07 Submission of Matters to a Vote of Security Holders A quorum was present at the Annual Meeting with 140,827,559 shares represented personally or by proxy, which represents approximately 90.45% of the outstanding shares of the Company's common stock. The voting results at the Annual Meeting were as set forth below. Proposal No. 1 – The shareholders voted to set the number of directors at nine:
For Against Abstain Broker Non-Vote
140,278,598 314,005 234,956 0
Proposal No. 2 – The shareholders elected each of the nominees to the Board of Directors:
For Against Abstain Broker Non-Vote
Robert V. Baumgartner 134,015,677 6,570,465 241,417 0
Julie L. Bushman 136,076,243 4,511,497 239,819 0
John L. Higgins 135,131,210 5,460,347 236,002 0
Kim Kelderman 139,472,895 1,087,500 267,164 0
Joseph D. Keegan 136,272,153 4,315,695 239,711 0
Alpna Seth 134,628,283 5,957,489 241,787 0
Rupert Vessey 137,441,139 3,145,646 240,774 0
Judith Klimovsky 138,104,299 2,120,409 602,851 0
Amy Herr 139,257,947 1,323,873 245,739 0
Each nominee was elected by a majority voting standard defined in the Amended and Restated Articles of Incorporation. Proposal No. 3 – The shareholders adopted a non-binding resolution approving the compensation of the Company’s named executive officers, as described in the Proxy Statement: 9,
For Against Abstain Broker Non-Vote
100,792,824 39,025,321 1,009,414 0
Proposal No. 4 – The shareholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2026. 40
For Against Abstain Broker Non-Vote
137,578,559 3,055,503 193,497 0
Item 8.01 Other Events A copy of the press release issued by Bio-Techne Corporation on November 5, 2025, announcing a cash dividend is attached hereto as Exhibit 99.2.
Item 9.01 Financial Statements and Exhibits (d) Exhibits
99.1 Press Release, dated November 5, 2025, announcing results of operations
99.2 Press Release, dated November 5, 2025, announcing cash dividend
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Sec
This page provides Bio-Techne Corp (TECH) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on TECH's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.